Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 3/2019

01-07-2019 | Anticoagulant | Original Article

Utility of Lupus Anticoagulant Assays (APTT-LA, KCT, DPT and DRVVT) in Detection of Antiphospholipid Syndrome (APS) in High Risk Pregnancy Cases

Authors: Ankur Ahuja, Seema Tyagi, Hara Prasad Pati, Renu Saxena, Venkatesan Somasundaram, Prabhu Manivannan, Preeti Tripathi, Dinesh Chandra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2019

Login to get access

Abstract

Routine investigation for recurrent pregnancy loss includes measurement of antiphospholipid antibodies. The lupus anticoagulant has long been associated with increased risks for thrombosis and adverse obstetric outcomes. But there are some disadvantages with lupus anticoagulant (LAC) tests which includes varied sensitivity of different clot based assays. ISTH recommends only 2 assays (preferably DRVVT and APTT-LA) for the identification of lupus anticoagulant but there are some studies which don’t support this contention. Our study analyzed 526 samples from high risk pregnancy cases for APLA by all four LAC tests from tertiary centre of northern India. Among all the cases studies 65 cases were positive for lupus anticoagulant 25 of this became negative after 12 weeks. Among the 40 repeated positive assays, dRVVT could able to diagnose 36 cases followed by APTT-LA which could able to diagnose 28 cases, while KCT could able to diagnose 23 cases and dPT could able to diagnose only 14 cases. There were 12 cases in whom all lupus assays were positive. Our study thus concluded that DRVVT was the most sensitive followed by APPT-LA, KCT, dPT. The combination of dRVVT with APTT-LA or KCT appeared to be superior to other combinations. No individual test per se is 100% sensitive for the diagnosis of APLA in high risk pregnancy cases. Further results confirmed that repeated LAC result is required even in a high-risk setting. Positive LAC assay in majority were not associated with exclusively recurrent pregnancy loss but were associated with sporadic stillbirth and thrombosis.
Literature
1.
2.
go back to reference Branch DW, Scott JR, Kochenour NK, Hershgold E (1985) Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313:1322–1326CrossRefPubMed Branch DW, Scott JR, Kochenour NK, Hershgold E (1985) Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313:1322–1326CrossRefPubMed
3.
go back to reference Pengo V, Tripodi A, Reber G et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7:1737–1740CrossRefPubMed Pengo V, Tripodi A, Reber G et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7:1737–1740CrossRefPubMed
4.
go back to reference Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr Rheum 42:1309–1311CrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthr Rheum 42:1309–1311CrossRef
5.
go back to reference Galli M, Reber G, de Moerloose P, de Groot PG (2008) Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 6:399–401CrossRefPubMed Galli M, Reber G, de Moerloose P, de Groot PG (2008) Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 6:399–401CrossRefPubMed
6.
go back to reference Galli M, Finazzi G, Bevers EM, Barbui T (1995) Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86:617–623PubMed Galli M, Finazzi G, Bevers EM, Barbui T (1995) Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 86:617–623PubMed
7.
go back to reference Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (2012) British committee for standards in haematology. Br J Haematol 157:47–58CrossRefPubMed Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (2012) British committee for standards in haematology. Br J Haematol 157:47–58CrossRefPubMed
8.
go back to reference Pengo V, Biasiolo A, Gresele P et al (2007) Participating centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 5:925–930CrossRefPubMed Pengo V, Biasiolo A, Gresele P et al (2007) Participating centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 5:925–930CrossRefPubMed
9.
go back to reference Jennings I, Mackie I, Arnout J, Preston FE (2004) UK national external quality assessment scheme for blood coagulation. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost 2:2178–2184CrossRefPubMed Jennings I, Mackie I, Arnout J, Preston FE (2004) UK national external quality assessment scheme for blood coagulation. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost 2:2178–2184CrossRefPubMed
10.
go back to reference Arnout J, Vanrusselt M, Huybrechts E, Vermylen J (1994) Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 87:94–99CrossRefPubMed Arnout J, Vanrusselt M, Huybrechts E, Vermylen J (1994) Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 87:94–99CrossRefPubMed
11.
go back to reference Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62:416–430PubMed Bowie EJ, Thompson JH Jr, Pascuzzi CA, Owen CA Jr (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62:416–430PubMed
12.
go back to reference Mueh JR, Herbst KD, Rapaport SI (1980) Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 92:156–159CrossRefPubMed Mueh JR, Herbst KD, Rapaport SI (1980) Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 92:156–159CrossRefPubMed
13.
go back to reference Clarke CA, Davidovits J, Spitzer KA, Laskin CA (2013) Lupus anticoagulant: results from 2257 patient attending a high risk pregnancy clinic. Blood 18(122):341–347CrossRef Clarke CA, Davidovits J, Spitzer KA, Laskin CA (2013) Lupus anticoagulant: results from 2257 patient attending a high risk pregnancy clinic. Blood 18(122):341–347CrossRef
14.
go back to reference Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K (2008) Thrombophilia and unexplained pregnancy loss in Indian patients. Natl Med J India 21:116–119PubMed Vora S, Shetty S, Salvi V, Satoskar P, Ghosh K (2008) Thrombophilia and unexplained pregnancy loss in Indian patients. Natl Med J India 21:116–119PubMed
15.
go back to reference Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J (2011) Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost 9:1776–1783CrossRefPubMed Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J (2011) Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost 9:1776–1783CrossRefPubMed
16.
go back to reference Helgadóttir LB, Turowski G, Skjeldestad FE, Jacobsen AF, Sandset PM, Roald B et al (2013) Classification of stillbirths and risk factors by cause of death—a case–control study. Acta Obstet Gynecol Scand 92:325–333CrossRefPubMed Helgadóttir LB, Turowski G, Skjeldestad FE, Jacobsen AF, Sandset PM, Roald B et al (2013) Classification of stillbirths and risk factors by cause of death—a case–control study. Acta Obstet Gynecol Scand 92:325–333CrossRefPubMed
17.
18.
go back to reference Miyakis S, Lockshin MD, Atsumi D, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi D, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed
19.
go back to reference Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, Tincani A, Lefkou E, Bertero MT et al (2015) The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14:387–395CrossRefPubMed Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, Tincani A, Lefkou E, Bertero MT et al (2015) The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14:387–395CrossRefPubMed
20.
go back to reference Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP et al (2014) Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 16(123):404–413CrossRef Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Marchetti T, Balducchi JP et al (2014) Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 16(123):404–413CrossRef
21.
go back to reference Fischer-Betz R, Specker C, Brinks R, Schneider M (2012) Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 21:1183–1189CrossRefPubMed Fischer-Betz R, Specker C, Brinks R, Schneider M (2012) Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 21:1183–1189CrossRefPubMed
22.
go back to reference Barbour LA (2001) ACOG committee on practice bulletins-obstetrics. Int J Gynaecol Obstet 75(2):203–212CrossRefPubMed Barbour LA (2001) ACOG committee on practice bulletins-obstetrics. Int J Gynaecol Obstet 75(2):203–212CrossRefPubMed
23.
go back to reference Branch DW, Silver RM, Porter TF (2010) Obstetric in antiphospholipid syndrome: current uncertainties should guide our way. Lupus 19:446–452CrossRefPubMed Branch DW, Silver RM, Porter TF (2010) Obstetric in antiphospholipid syndrome: current uncertainties should guide our way. Lupus 19:446–452CrossRefPubMed
24.
go back to reference Skrzypczak J, Rajewski M, Wirstlein P, Goździewicz T, Zimmer M, Wołczyński S et al (2011) Frequency of antiphospholipid syndrome in women with pregnancy loss in multicenter study in Poland. Ginekol Pol 82:749–754PubMed Skrzypczak J, Rajewski M, Wirstlein P, Goździewicz T, Zimmer M, Wołczyński S et al (2011) Frequency of antiphospholipid syndrome in women with pregnancy loss in multicenter study in Poland. Ginekol Pol 82:749–754PubMed
25.
go back to reference Martinuzzo ME, Cerrato GS, Varela ML, Adamczuk YP, Forastiero RR (2012) New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests. Int J Lab Hematol 34:208–213CrossRefPubMed Martinuzzo ME, Cerrato GS, Varela ML, Adamczuk YP, Forastiero RR (2012) New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests. Int J Lab Hematol 34:208–213CrossRefPubMed
26.
go back to reference Exner T, Rickard KA, Kronenberg H (1978) A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 40:143–151CrossRefPubMed Exner T, Rickard KA, Kronenberg H (1978) A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 40:143–151CrossRefPubMed
27.
go back to reference Pengo V, Biasiolo A, Rampazzo P, Brocco T (1999) dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 81:256–258CrossRefPubMed Pengo V, Biasiolo A, Rampazzo P, Brocco T (1999) dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 81:256–258CrossRefPubMed
28.
go back to reference Urbanus RT, de Groot PG (2011) Antiphospholipid antibodies—we are not quite there yet. Blood Rev 25:97–106CrossRefPubMed Urbanus RT, de Groot PG (2011) Antiphospholipid antibodies—we are not quite there yet. Blood Rev 25:97–106CrossRefPubMed
Metadata
Title
Utility of Lupus Anticoagulant Assays (APTT-LA, KCT, DPT and DRVVT) in Detection of Antiphospholipid Syndrome (APS) in High Risk Pregnancy Cases
Authors
Ankur Ahuja
Seema Tyagi
Hara Prasad Pati
Renu Saxena
Venkatesan Somasundaram
Prabhu Manivannan
Preeti Tripathi
Dinesh Chandra
Publication date
01-07-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-01072-8

Other articles of this Issue 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine